Aurora Cannabis sees Q2 revenue growth y/y

“For Q2 2026, we expect to see consolidated net revenue increase year over year, driven primarily by 8% to 12% growth in our Global Medical Cannabis segment. Plant propagation net revenue is expected perform in line with traditional seasonal trends, as 25% to 35% of revenues are normally earned in the second half of a calendar year. Consolidated adjusted gross margins are expected to increase, driven primarily by 250 to 475 basis points growth in our cannabis business, with plant propagation adjusted gross margins expected to mostly perform in line with historical trends. Improvements in our adjusted gross margins and higher global medical cannabis revenue, should lead to continued strong positive adjusted EBITDA. While free cash flow is expected to be positive on an annual basis for the second consecutive year, there will be several significant cash outflows, in line with historical trends, that will impact free cash flow results in Q2 2026.”